RWLK - Auch REWALK lässt Gelähmte wieder gehen - Exoskelett Stocks die Highflyer von morgen??? - 500 Beiträge pro Seite

[Findik2]

Ihr kennt ja evtl. schon die Story von meinem EKSO Thread. Deshalb habe Ich mich kurzerhand entschloßen zum Mitbewerber auch ein Thread zu eröffnen. Ziemlich gleiche Story mit dem Unterschied RWLK ist bereits an der Nasdaq und hat teilw. FDA Zulassung erhalten.

Ja die Überschrift ist etwas reißerisch.

Unter bestimmten Vorraussetzungen ist dies mit dem Ekso Skelett möglich. Ich bin von der Idee fasziniert das manche Gehbehinderte wieder in absehbarerer Zeit die Chance bekommen werden wieder laufen zu können.

Auch für das Militär soll das Skelett zum Schwerlasttransport zum Einsatz kommen. 100 kg Lasten könnten dann von einen Soldaten zu Fuß getragen werden.

Leider sehr wenig Infos über die Zahlen und Aussichten … wer Infos hat einfach posten.

WKN: -
ISIN: IL0011331076
Webseite: rewalk.com
Video von Lauferfolgen: http://youtu.be/2Xd27c-pz4Y
Was sind Exoskelette: http://de.wikipedia.org/wiki/Exoskelett

Der Beitrag stellt keine Kauf/Verkaufsempfehlung dar und dient lediglich zu Informationszwecken über das Unternehmen.

[Findik2]

http://globenewswire.com/news-release/2015/04/23/727860/1013…

RWLK veröffentlicht am 07.05. Ihre Zahlen. Viel wird nicht gehen aber wenn die "Sales" Posten leicht ansteigen könnte der Abwärtstrend evtl. gestoppt werden. Ich bleibe im Beobachtungsmodus

[Findik2]

http://www.satprnews.com/2015/05/04/rewalk-robotics-to-prese…

Konferenz 10.05. in Tel Aviv mit Kevin Hershberger, Chief Financial Officer von ReWalk

[Findik2]

http://www.marketwatch.com/story/rewalk-robotics-reports-fir…" target="_blank" rel="nofollow ugc noopener">http://www.marketwatch.com/story/rewalk-robotics-reports-fir…




ReWalk Robotics Reports First Quarter 2015 Financial Results

Published: May 7, 2015 6:50 a.m. ET

0
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., May 07, 2015 (GLOBE NEWSWIRE via COMTEX) --

ReWalk Robotics Ltd. RWLK, +3.79% ("ReWalk" or "the Company") today announced its financial results for the three months ended March 31, 2015.

Highlights of and subsequent to the first quarter include:

Total revenue was $635,000 compared to $445,000 during the first quarter of 2014, an increase of 43% year-over-year but a sequential decline from $1.5 million in the fourth quarter of 2014;

13 ReWalk systems were placed during the first quarter of 2015 compared to six systems during the first quarter of 2014 and 31 systems during the fourth quarter of 2014;

Received new coverage decisions with a commercial private insurer and Workers' Compensation groups in the U.S., and Germany;

Broadened our presence in the leading rehabilitation centers in the United States – to include eight of the top 10 rehabilitation centers in the U.S. (US News & World Report Rehabilitation & Hospital rankings), and added 10 new training centers in the first quarter of 2015; and

Established new partnerships to distribute the ReWalk exoskeleton systems in Northern India and Denmark.
"Sales this quarter were less than expected as the number of units placed were impacted by longer cycle times to complete patient evaluation, training, and processing of reimbursement claims," said Larry Jasinski, Chief Executive Officer.

"During the quarter we made excellent progress in building our overall training infrastructure, expanding market awareness and creating a high level of qualified customer demand. Due to stronger customer interest, we are now directing more qualified leads to our training centers, which we believe will result in higher sales. April commitments are already equal to first quarter sales, and we have two months remaining in Q2. Our outlook remains positive for growth over the course of the year," he added.

"Our strategic plan for initial case-by-case reimbursement along with parallel long-term activities is the key to achieving our overall growth targets. The experienced reimbursement team we have recruited has begun to build the infrastructure we need to enable more individuals to obtain coverage for their systems in the short term and will be able to support market growth over the next few years." Jasinski concluded.

First Quarter 2015 Financial Results

Total revenue was $635,000 for the first quarter of 2015, up 43% compared with $445,000 in the first quarter of 2014, due to higher placements of ReWalk systems during the first quarter of 2015. In the first quarter of 2015, 13 ReWalk systems were placed compared with six ReWalk systems placed in the prior year period.

Gross profit for the first quarter of 2015 was $33,000 as compared to a gross loss of $0.2 million in the first quarter of 2014. This was largely due to the positive impact of moving manufacturing operations to Sanmina in the second half of 2014.

Total operating expenses in the first quarter of 2015 were $5.6 million, compared with $2.8 million in the first quarter of 2014, and reflects the Company's increased investment in sales, marketing, and research and development resources and the increased cost of being a publicly-traded company.

Net loss was $5.7 million for the first quarter of 2015 compared with $5.1 million in the prior year quarter. Non-GAAP net loss for the first quarter of 2015 was $5.1 million compared with non-GAAP net loss of $2.9 million in the prior year quarter.

A reconciliation of net loss to non-GAAP net loss is included at the end of this press release.

Liquidity

As of March 31, 2015, ReWalk had $37 million in cash and cash equivalents.

Guidance

The Company is providing top-line guidance of $7 million to $10 million for 2015 based on its anticipated sales ramp for the ReWalk system.


Conference Call

ReWalk management will host its third quarter conference call as follows:

Date Thursday, May 7, 2015
Time 8:30 AM EDT
Telephone U.S: [phone]
International: [phone]
Israel: 18 09 31 53 62
Access code 28392703
Webcast (live and archive) www.rewalk.com under the "Investors" section.
A telephone replay will be available shortly after the completion of the call for two weeks at [phone] (U.S.) or [phone] (International). The passcode for the replay is 28392703.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

Forward Looking Statements

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, as amended and other securities laws. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "intends," "anticipate(s)," "look forward," "upcoming," "plan," "enables," "potentially," "entitles," and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the anticipated revenues and underlying sales for the first quarter and fiscal 2015; future availability of reimbursement for ReWalk in Germany and the United States; and the successful and timely achievement of favorable coverage decisions for ReWalk by additional major insurers. All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to the following: the market for medical exoskeletons is new and unproven, and important assumptions about the potential market for our products may be inaccurate; the Company has a limited operating history upon which you can evaluate our business plan and prospects; if we are unable to expand our sales, marketing and training infrastructure, we may fail to increase our sales; the health benefits of ReWalk have not been substantiated by long-term clinical data, which could limit sales; the Company may fail to secure or retain adequate coverage or reimbursement for ReWalk by third-party payers; the Company depends on a single third-party to manufacture ReWalk and a limited number of third-party suppliers for certain components of ReWalk; the Company's future growth and operating results will depend on our ability to develop and commercialize new products and penetrate new markets; the Company operates in a competitive industry that is subject to rapid technological change, and we expect competition to increase; and the Company is subject to extensive governmental regulations relating to the manufacturing, labeling and marketing of our products. These and other risk factors are set forth in the Company's final Annual Report on Form 20-F for the year-ended December 31, 2014 filed with the Securities and Exchange Commission on February 27, 2015, and our other reports filed from time to time with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. ReWalk does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of non-GAAP accounting measures, including non-GAAP net loss is helpful to its investors. These measures, which the Company refers to as our non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three-months ended March 31, 2015 and 2014, non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense and (ii) the revaluation of warrants to purchase convertible preferred shares.

Because of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash expenses, the Company believes that providing non-GAAP financial measures that exclude share-based compensation expense and non-cash financial (income) expenses allow for more meaningful comparisons between our operating results from period to period. Each of our non-GAAP financial measures is an important tool for financial and operational decision-making and for evaluating our own operating results over different periods of time. The non-GAAP financial data are not measures of our financial performance under U.S. GAAP, and should not be considered as alternatives to operating loss or net loss or any other performance measures derived in accordance with GAAP. Non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial results differently, particularly related to non-recurring, unusual items. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. Further, share-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of the compensation provided to our employees. The presentation of non-GAAP financial information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. ReWalk urges investors to review the reconciliation of our non-GAAP financial measures to the comparable GAAP financial measures included below, and not to rely on any single financial measures to evaluate our business.

(tables follow)

ReWalk Robotics Ltd.
Condensed Consolidated Statements of Operations
In thousands except per share data
(unaudited)

Three months ended March 31,
2015 2014

Revenue $ 635 $ 445
Cost of revenues 602 643

Gross profit (loss) 33 (198)

Operating expenses:
Research and development 1,537 1,082
Sales and marketing 2,518 1,215
General and administration 1,499 540
Total operating expenses 5,554 2,837

Operating loss (5,521) (3,035)

Financial expenses, net (169) (2,005)
Loss before income taxes (5,690) (5,040)

Income taxes 16 11

Net loss (5,706) (5,051)

Convertible preferred shares dividend -- (687)

Net loss attributable to ordinary shares $ (5,706) $ (5,738)

Net loss per ordinary share, basic and diluted $ (0.48) $ (30.69)

Weighted average shares outstanding, basic and diluted 12,007.16 186.98


Reconciliation of GAAP to Non-GAAP net loss
Net loss $ (5,706) $ (5,051)
Non-cash share based compensation expense 586 152
Revaluation of fair value of warrants to purchase convertible preferred share -- 1,992
Non-GAAP net loss $ (5,120) $ (2,907)

ReWalk Robotics Ltd.
Condensed Consolidated Balance Sheets
In thousands

March 31, December 31,
2015 2014
Assets Unaudited Audited

Current assets
Cash & cash equivalents $ 36,963 $ 41,829
Short-term deposits -- 1,667
Accounts receivable 1,702 1,955
Other short-term assets 1,196 756
Inventory 1,836 777
Total current assets 41,697 46,984

Other long-term assets 249 267
Properties and equipment, net 741 414

Total assets $ 42,687 $ 47,665

Liabilities and equity

Current liabilities
Accounts payable $ 2,158 $ 1,390
Other liabilities 1,505 2,184
Total current liabilities 3,663 3,574

Other long-term liabilities 224 238
Shareholders' equity 38,800 43,853
Total liabilities and equity $ 42,687 $ 47,665

ReWalk Robotics Ltd.
Condensed Consolidated Statements of Cash Flows
In thousands
(unaudited)

Three months ended March 31,
2015 2014

Net cash used in operating activities $ (6,162) $ (3,503)

Net cash provided by (used in) investing activities 1,296 (201)

Net cash provided by financing activities -- 2

Decrease in cash and cash equivalents (4,866) (3,702)

Cash and cash equivalents at beginning of period 41,829 8,860

Cash and cash equivalents at end of period $ 36,963 $ 5,158

ReWalk Robotics Ltd.
Revenue and Units Placed by Region
In thousands except units
(unaudited)

Three months ended March 31,
2015 2014
Revenue:
United States $ 575 $ 329
Europe 60 116
Asia Pacific -- --
Israel -- --
Total Revenue $ 635 $ 445

Units Placed:
United States 10 4
Europe 3 2
Asia Pacific -- --
Israel -- --
Total Unit Placed 13 6
CONTACT: Investor Contact: Lisa M. Wilson President In-Site Communications, Inc. T: 212-452-2793 E: [e-mail]
Copyright (C) 2015 GlobeNewswire, Inc. All rights reserved.

[Findik2]

William Plovanic von Cannacord Genuity hat am Freitagmorgen seine Analysenschätzung das Kursziel von 11 auf 17 $ gehoben.

Der Kurs ist momentan in einer kurzfristigen Aufwärtsbewegung. Theoretisch sollte er nach dem Heißlaufen der News wieder abfallen. Was meint Ihr? Die Bilanz von RWLK war ja sehr mau... und das Kursziel mit dem "first mover bonus" zu begründen ist m.M. nichts nachhaltiges. Momentan wird's wohl wieder runter gehen. Ich warte auf bessere Einstiegskurse. Firma ist nach gesundem Menschenverstand zu handeln noch zu teuer da 1. so gut wie kein Umsatz / Sales und 2. Die Zukunftsaussichten noch nicht sicher sind Beispiel Abrechnung mit Krankenkassen, langfristige Erfolge etc.

Das kann hier was großes werden jedoch warte Ich an der Seitenlinie. Sagt mir eure Meinung!

Hier noch ein paar Links zu meinem obigen schreiben:

http://www.analystratings.com/2015/05/22/rewalk-robotics-got…" target="_blank" rel="nofollow ugc noopener">http://www.analystratings.com/2015/05/22/rewalk-robotics-got…

http://www.wallstreetsectorselector.com/investment-articles/…" target="_blank" rel="nofollow ugc noopener">http://www.wallstreetsectorselector.com/investment-articles/…


Keine Kauf Verkauf oder Handelsempfehlung nur meine persönliche Meinung.

[Findik2]

ReWalk Robotics: Another Quarter Of Uncertainty Will Lead Shares Lower

Summary

RWLK had a disappointing quarter to say the least but the Q1/15 conference call might have made things worse.
RWLK management dodged specifically answering just about every question on the call - but they did highlight the highlights which was nice.
RWLK management either needs to execute to a point that questions don't come up or be able to give anything of specifics.
With so much uncertainty and an accelerating cash burn I continue to recommend readers avoid RWLK


Seekingalpha Artikel über Rewalk:

http://seekingalpha.com/article/3222366-rewalk-robotics-anot…" target="_blank" rel="nofollow ugc noopener">http://seekingalpha.com/article/3222366-rewalk-robotics-anot…

[Findik2]

Rewalk Robotics Downgraded by Zacks to Sell (RWLK)

http://www.dakotafinancialnews.com/rewalk-robotics-downgrade…" target="_blank" rel="nofollow ugc noopener">http://www.dakotafinancialnews.com/rewalk-robotics-downgrade…

[sundancer-ch]

noch jemand am Leben hier?

[Findik2]

Antwort auf Beitrag Nr.: 51.120.279 von sundancer-ch am 18.11.15 16:49:47

Ja bin noch hier ^^ hab nix mehr gepostet weil Ich dachte liest es keiner mehr mit. Bin nicht investiert, finde die Branche an sich interessant. Hast ne Meinung zu RWLK?

[Findik2]

Und wenns dich auch Interessiert hier die "4 großen und kleinen Player":

http://www.cyberdyne.jp/english/

http://intl.eksobionics.com/german

http://rewalk.com/de/

http://www.parker.com/

[sundancer-ch]

hab letztens mal nen Bericht darüber gesehen und hatte den Wert seitdem in der Watchlist und heute den Anstieg angezeigt bekommen. Sehr interessant was die so treiben. Vorallem was sehr positives

[Findik2]

Habe mir mal den Spass erlaubt RWLK mit EKSO in Verbindung zu setzen. Beide haben eine wahnsinnig hohe Cashburnrate! RWLK scheint noch ein bisschen mehr Luft aufgrund des Cashbestandes von 25 Mio zu haben. Die Gross Profit Marge ist Katastrophal. Hier wird es ende 2016 wohl eng werden. Schade eigentlich das solche Worldchanger den Durchbruch noch nicht schaffen. Bleibt aber auf der WL!

RWLK / EKSO

Für 3. Quartal 2015:
32,968 Total assets 22,126
32,968 Total liabilities 12,880

1,165 Total revenue 2,915
1,078 Total cost of revenue 2,447
87 Gross profit 468

6,392 Total operating expenses 5,649!!!
(6,305) Loss from operations (5,181)

Für 9 Monate in 2015:
(5,999) Net cash used in operating activities (13,082)
(6,034) Net increase (decrease) in cash (13,952)
31,172 Cash at beginning of the period 25,190
25,138 Cash at end of the period 11,238

Keine Kauf / Verkauf / Handelsempfehlung und keine Garantie auf Richtigkeit.

[Findik2]

http://www.streetinsider.com/Corporate+News/ReWalk+Robotics+…

hmm damit konnte man nicht rechnen. Schöne fast 100% Interday. Ob es nachhaltig ist wird sich zeigen.
Das ist auf jedenfall mal ein Strohhalm an den Sie sich klammern können.

[jhackel]

Schon wieder sundancer und der findik hier
Ich kann euch schon nicht mehr sehen.

Ist denn irgendwas hier erkennbar, welchen Umsatzsprung das bringen wird?

[Findik2]

Antwort auf Beitrag Nr.: 51.334.758 von jhackel am 18.12.15 16:22:59

Schau auf die MK da ist m.M. viel Zukunft schon mit drin eingespeist. Kann sehr schnell hoch oder auch wieder runter gehen.

http://www.ctvnews.ca/sci-tech/u-s-veterans-affairs-to-pay-f…

Published Thursday, December 17, 2015 3:12AM EST
The Department of Veterans Affairs has agreed to pay for robotic legs that could allow scores of paralyzed veterans with spinal cord injuries to walk again.
Veterans have been petitioning the VA to do this because many cannot afford the $77,000 needed to pay for the powered exoskeleton called the ReWalk. The device was approved by the U.S. Food and Drug Administration in 2014 for individuals to use at home. VA officials told The Associated Press that that the agency sent a memorandum Dec. 10 outlining its plans to train staff to be able to provide the ReWalk.
"The research support and effort to provide eligible veterans with paralysis an exoskeleton for home use is a historic move on the part of the VA because it represents a paradigm shift in the approach to rehabilitation for persons with paralysis," said Dr. Ann Spungen, who led VA research on the system.
PHOTOS
Paralyzed US veterans to get robotic legs
ReWalk Robotics service engineer Tom Coulter, right, moves paralyzed Army veteran Gene Laureano's wheelchair, as Laureano prepares to walk using a ReWalk device in Bronx, N.Y. on Wednesday, Dec. 16, 2015. (AP / Mel Evans)
The company, ReWalk Robotics, said it has evaluated 45 paralyzed veterans who meet the height and weight requirements for the technology - which consists of leg braces with motion sensors and motorized joints that respond to subtle changes in upper-body movement and shifts in balance.
Gene Laureano, 53, is praying his application for robotic legs will go through soon. The former Army corporal remembers the day he first tried the ReWalk at New York's James J. Peters VA Medical Center in the Bronx two years ago.
"The tears came down," said Laureano, who was left paralyzed five years ago after falling off a ladder. "I hadn't spoken to somebody standing up in so long."
"I just kept remembering the doctor told me it was impossible for me to walk, and then I crossed that threshold from the impossible to the possible," he added.
When the study ended, however, so did his ability to walk. He's been waiting to get the robotic legs ever since.
Paralyzed veterans fired off letters to VA Secretary Robert McDonald this summer.
"I guess people who have been watching the research were very anxious and had expectations this would suddenly happen once FDA approval came out, but we were still building the infrastructure to support this great device," VA spokesman Jim Connell said.
The ReWalk was invented by Israeli entrepreneur Amit Goffer, who was paralyzed in an accident in 1997. Several competing products that use similar technology - nicknamed "electronic legs"- are also being tested in U.S. rehab hospitals.
None, including the ReWalk, are fast enough or can be worn long enough to replace wheelchairs. VA pilot studies found paraplegics who used the exoskeleton as little as four hours a week for three to five months experienced better bowel and bladder function, reduced back pain, improved sleep and less fatigue.
About 42,000 veterans are paralyzed. Of them, a fraction would meet the requirement for an exoskeleton. The apparatus requires specific height and weight requirements and works for paraplegics but not for quadriplegics. A supportive belt around the patient's waist keeps the suit in place, and a backpack holds the computer and rechargeable battery. Crutches are used for stability, and the FDA requires an assistant be nearby.
ReWalk Robotics CEO Larry Jasinski said a dozen VA centres are expected to start training staff to provide the system. The program will likely be expanded in the future.
Former Army Sgt. Terry Hannigan, a 62-year-old paralyzed Vietnam veteran, was the first veteran to get the robotic legs as part of a test of the system. She uses them to walk through the mall and shop at the grocery store.
"It definitely is a show stopper, especially in the mall with kids. Some say things like 'Wow, look at Robocop!"' They ask a lot of questions, but I don't mind," Hannigan said.
When she was confined to a wheelchair she said she had to ask people to pass her things out of her reach.
"To be able to hear the conversation, not miss half of what's being said because it's over your head, that in itself is a big plus," she said. "Now I can walk up, shake someone's hand. I can hug, kiss them. That might be a small thing, but the only other time I would get body contact was when a family member or caregiver would pick me up and put me in bed."

[jhackel]

Ich weiß nicht ob das schon diskutiert wurde. Aber Rewalk hat einen Kredit aufgenommen, mit Warrants.
Zur Info: Anscheinend haben gewisse Fonds einen legalen Weg gefunden, mittels Warrants die Aktienanzahl massiv zu erhöhen und die Altaktionäre auf diesem Wege quasi zu enteignen.

http://seekingalpha.com/news/3010936-rewalk-secures-20m-line…

Ich habe mir das Vertragswerk von Rewalk nicht angeschaut. Jedoch schrillen bei mir die Alarmglocken, wenn ich solche Sätze lese.

Additional draw downs by ReWalk will increase the warrant amount by 5.75% of the value of the draw downs.

Keine Handelsempfehlung, soll jeder machen was er will damit. Ich mache einen großen Bogen um solche Buden. Siehe jüngste Opfer AEZS und GBSN.

[Findik2]

Die Story war gut aber wie befürchtet ist die Aktie über das Jahr 2016 massiv abgeschmiert. Ich werde bei Gelegenheit mich mal wieder in die Bilanzen einlesen.